

Immunology Innovation Program

Developing Antibodies to Novel Targets via Co-creation

argenx is a global immunology company **committed to improving the lives of those with severe autoimmune diseases.** We are developing a broad portfolio of antibody therapies to novel targets, including the first approved neonatal Fc receptor (FcRn) blocker

We are looking to **co-create with leading translational biologists and clinicians** to guide the discovery and development of novel therapeutics utilizing our **cutting-edge SIMPLE Antibody™ Platform and engineering technologies**

CLINICAL
DEVELOPMENT

DISEASE
INSIGHT

Learn more
about our Immunology
Innovation Program!

Learn more
about our antibody
technologies!



us.argenx.com/innovation

argenx



Leading
Translational
Biology Labs



us.argenx.com/innovation#antibody

ANTIBODY
ENGINEERING

TECHNOLOGY
KNOW-HOW

By **combining our antibody engineering capabilities with physician/scientists' expertise,** we aim to translate immunology breakthroughs into novel antibody-based medicines to continue to **transform patients' lives.**

Connect with us via
IIP@argenx.com